Equity · Healthcare
BMY
NYSEBristol-Myers Squibb Company (BMY)
The line runs 65.43 USD on 3 August through 62.47 USD on 30 October, on a scale from 55 to 70. Days the market did not trade hold the previous close, flat.
- Market cap
- 127.7B USD
- P/E (TTM)
- 13.8
- Revenue, year to Dec 2025
- 48.2B USD
- EPS, diluted, year to Dec 2025
- 3.46 USD
- 52-week range
- 42.64 USD – 68.08 USD
- Avg volume
- 813.9K
- Mentions, 30 days
- 6
- Net sentiment
- +0.14
as of Oct 30, 2026
Have Bristol-Myers Squibb Company (BMY) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Bristol-Myers Squibb Company insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Mar 2026, show no open-market purchase.
Form 4, 90 days to 1 Nov 2026, newest reported trade 9 Sep 2026
Buys 0Sells 2Net sold $437KOther filings 4
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Sep 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Sell | 6,249 | 403K USD |
| 25 Aug 2026 | Holzer Phil MSVP and Controller | Sell | 500 | 34K USD |
| Sold | 2 open-market sales | 6,749 | $437K |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Oct 2026 | Gallman CariEVP, General Counsel | Option exercise | 4,559 | |
| 02 Oct 2026 | Gallman CariEVP, General Counsel | Tax withheld | 2,332 | 143K USD |
| 01 Sep 2026 | Short Bartie WendyEVP, Corporate Affairs | Option exercise | 1,236 | 83K USD |
| 01 Sep 2026 | Short Bartie WendyEVP, Corporate Affairs | Tax withheld | 633 | 42K USD |
Which funds hold Bristol-Myers Squibb Company (BMY)?
10 of the 45 institutional funds we track reported a Bristol-Myers Squibb Company position for the quarter ended 30 Jun 2026 — a combined 2.6B USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 27,357,486 | 1.6B USD | −7.7% |
| Two Sigma Investments | Held (±25%) | 10,085,383 | 581.1M USD | −12.6% |
| Man Group | Held (±25%) | 4,682,000 | 269.8M USD | −17.3% |
| Citadel Advisors | Held (±25%) | 1,572,329 | 90.6M USD | +5.2% |
| Millennium Management | Trimmed | 752,576 | 43.4M USD | −88.5% |
| D. E. Shaw & Co. | Added | 559,407 | 32.2M USD | +80.5% |
| Fisher Asset Management | Held (±25%) | 173,404 | 10.0M USD | −14.9% |
| Balyasny Asset Management | Trimmed | 88,288 | 5.1M USD | −25.6% |
| GAMCO Investors | Held (±25%) | 82,671 | 4.8M USD | −5.0% |
| Marshall Wace | Trimmed | 15,169 | 874K USD | −99.6% |
Have members of Congress traded Bristol-Myers Squibb Company (BMY)?
The most recent congressional trade disclosed in Bristol-Myers Squibb Company is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 19 Dec 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 19 Dec 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 24 days |
| 18 Dec 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 28 days |
| 13 Nov 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 28 days |
| 12 Nov 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 33 days |
| 14 Aug 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 28 days |
| 24 Jun 2025 | Virginia Foxxhouse · Republican–NC | Sale | 1K USD–15K USD | 9 days |
| 12 May 2025 | Jefferson Shrevehouse · Republican–IN | Sale | 15K USD–50K USD | 41 days |
| 28 Apr 2025 | Julia Letlowhouse · Republican–LA | Sale | 1K USD–15K USD | 260 days |
Bristol-Myers Squibb Company (BMY) US federal contracts
US federal agencies committed 8.8M USD in contracts to Bristol-Myers Squibb Company (BMY) in fiscal 2026, the year to 30 Sep 2026, against 7.6M USD the year before.
USAspending.gov
Fiscal 2027 so far 1.0M USDFiscal 2026 8.8M USDFiscal 2025 7.6M USDFiscal 2024 3.4M USD
| Signed | Agency | Contract | Committed |
|---|---|---|---|
| 01 Oct 2026 | Department of Veterans Affairs | CAMZYOS AND POMALYSTDRUGS AND BIOLOGICALS · 36C24527N0033 | 1.0M USD |
| 06 Aug 2026 | Department of Veterans Affairs | BREYANZI INJECTIONDRUGS AND BIOLOGICALS · 36C24926N0658 | 364K USD |
| 06 Aug 2026 | Department of Veterans Affairs | ABECMA INJECTIONDRUGS AND BIOLOGICALS · 36C24926N0651 | 379K USD |
| 02 Aug 2026 | Department of Veterans Affairs | POMALYST 2 MG, 3 MG,4 MGDRUGS AND BIOLOGICALS · 36C24526N0790 | 199K USD |
| 02 Aug 2026 | Department of Veterans Affairs | MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)DRUGS AND BIOLOGICALS · 36C24526N0776 | 300K USD |
| 07 Jul 2026 | Department of Veterans Affairs | POMALYST 2 MG, 3 MG,4 MGDRUGS AND BIOLOGICALS · 36C24526N0715 | 138K USD |
| 16 Jun 2026 | Department of Veterans Affairs | BREYANZI CAR T - TRANSPLANTDRUGS AND BIOLOGICALS · 36C24926N0591 | 364K USD |
| 16 Jun 2026 | Department of Veterans Affairs | BREYANZI CAR T - TRANSPLANTDRUGS AND BIOLOGICALS · 36C24926N0590 | 364K USD |
| 16 Jun 2026 | Department of Veterans Affairs | BREYANZI CAR TDRUGS AND BIOLOGICALS · 36C24926N0589 | 364K USD |
| 02 Jun 2026 | Department of Veterans Affairs | BREAYNAZI FOR CAR-T TRANSPLANT MEDICATIONDRUGS AND BIOLOGICALS · 36C24926N0433 | 364K USD |
Newest first: 10 of 62 contracts. Contracts of US$100,000 or more signed since April 2022; the amount is what the government has committed so far, which grows when options are exercised. Defense Department contracts are published about 90 days after signing, so the latest year is still filling in.
What has been filed or recorded for Bristol-Myers Squibb Company (BMY)?
The filings we hold for Bristol-Myers Squibb Company, newest first: 10 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 909 shares | 52K USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,894 shares | 282K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 181 shares | 11K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 815 shares | 49K USD notional · <0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,644 shares | 396K USD notional · <0.001% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 4 shares | 235 USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 100 shares | 6K USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 330 shares | 21K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 1.05 USD | Revenue $13.07B |
| 30 Sep 2026 | Financials | Total assets | 88.8B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 23.4B USD | at period end |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 5,176 shares | 325K USD notional · <0.001% of shares out |
| 21 Sep 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 63 USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 1.62 USD | Revenue $12.97B |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 1.31 USD | Revenue $11.49B |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 3.46 USD | Revenue $48.19B |
| 31 Dec 2025 | Financials | Revenue | 48.2B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 7.1B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 3.46 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 1.08 USD | Revenue $12.22B |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.64 USD | Revenue $12.27B |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 1.20 USD | Revenue $11.20B |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.41 USD | Revenue $48.30B |
What is Reddit saying about Bristol-Myers Squibb Company (BMY)?
Reddit mentioned BMY 6 times in the 30 days to 1 November 2026, across 3 of the communities we track. All of them were scored for sentiment: 83% read bullish, 0% bearish and 17% neither. Reddit data updated 1 November 2026.
30-day window, Method
Mentions, 30 days 6Bullish 83%Bearish 0%Communities 3Against the market +29 points
How do Reddit mentions of Bristol-Myers Squibb Company (BMY) compare with its price?
Share ↗
Where Bristol-Myers Squibb Company (BMY) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 67% | 4 | +0.16 |
| r/investing | 17% | 1 | +0.02 |
| r/stocks | 17% | 1 | +0.21 |
Bristol-Myers Squibb Company (BMY): frequently asked questions
What did Bristol-Myers Squibb Company shares close at?
Bristol-Myers Squibb Company closed at 62.47 USD on 30 Oct 2026, up 1.74% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company is worth 127.7B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Bristol-Myers Squibb Company’s P/E ratio?
Bristol-Myers Squibb Company has a price-to-earnings ratio of 13.8, as of 30 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Bristol-Myers Squibb Company’s revenue?
Bristol-Myers Squibb Company reported revenue of 48.2B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Bristol-Myers Squibb Company insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Bristol-Myers Squibb Company insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Mar 2026, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Bristol-Myers Squibb Company?
10 of the 45 funds we track reported a Bristol-Myers Squibb Company position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Man Group. See Funds
Have members of Congress traded Bristol-Myers Squibb Company?
Yes. 26 trades in Bristol-Myers Squibb Company appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 19 Dec 2025, filed 12 Jan 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Bristol-Myers Squibb Company last report earnings?
Bristol-Myers Squibb Company last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.05 USD; no next date is announced in SEC filings yet. See Filings
Does Bristol-Myers Squibb Company have government contracts?
Yes. US federal agencies committed 8.8M USD in contracts to it in fiscal 2026, the year to 30 Sep 2026 (USAspending.gov). See Contracts
What is Reddit saying about Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company was mentioned 1 times in the last 7 days across the finance subreddits we track, and 6 times over the trailing 30 days. Of the 6 mentions scored for sentiment, 83% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- USAspendingUSAspending.gov (U.S. Department of the Treasury), federal prime contract awards
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Bristol_Myers_Squibb